Page 85 - Read Online

Page 14 of 15 Osho et al. Hepatoma Res 2020;6:55 I http://dx.doi.org/10.20517/2394-5079.2020.42

64. Sirlin CB, Hussain HK, Jonas E, Kanematsu M, Min Lee J, et al. Consensus report from the 6th International forum for liver MRI using
gadoxetic acid. J Magn Reson Imaging 2014;40:516-29.
65. Lu RC, She B, Gao WT, Ji YH, Xu DD, et al. Positron-emission tomography for hepatocellular carcinoma: Current status and future
prospects. World J Gastroenterol 2019;25:4682-95.
66. Brix G, Ziegler SI, Bellemann ME, Doll J, Schosser R, et al. Quantification of [(18)F]FDG uptake in the normal liver using dynamic PET:
impact and modeling of the dual hepatic blood supply. J Nucl Med 2001;42:1265-73.
67. Wudel LJ Jr., Delbeke D, Morris D, Rice M, Washington MK, et al. The role of [18F]fluorodeoxyglucose positron emission tomography
imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69:117-24; discussion 124-6.
68. Jadvar H. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission
tomography radiotracers. Semin Nucl Med 2012;42:247-54.
69. Ehman EC, Johnson GB, Villanueva-Meyer JE, Cha S, Leynes AP, et al. PET/MRI: Where might it replace PET/CT? J Magn Reson
Imaging 2017;46:1247-62.
70. Hernandez R, Sun H, England CG, Valdovinos HF, Ehlerding EB, et al. CD146-targeted immunoPET and NIRF imaging of hepatocellular
carcinoma with a dual-labeled monoclonal antibody. Theranostics 2016;6:1918-33.
71. Jo PC, Jang HJ, Burns PN, Burak KW, Kim TK, et al. Integration of contrast-enhanced US into a multimodality approach to imaging of
nodules in a cirrhotic liver: how I do it. Radiology 2017;282:317-31.
72. Kim TK, Noh SY, Wilson SR, Kono Y, Piscaglia F, et al. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system
(LI-RADS) 2017 - a review of important differences compared to the CT/MRI system. Clin Mol Hepatol 2017;23:280-9.
73. Zhang J, Yu Y, Li Y, Wei L. Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence
from 1998 to 2016. Oncotarget 2017;8:75418-26.
74. Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand?
Ultrasonography 2019;38:200-14.
75. Aubé C, Oberti F, Lonjon J, Pageaux G, Seror O, et al; CHIC Group. EASL and AASLD recommendations for the diagnosis of HCC to
the test of daily practice. Liver Int 2017;37:1515-25.
76. Vilana R, Forner A, Bianchi L, García-Criado A, Rimola J, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may
display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010;51:2020-9.
77. Chen LD, Xu HX, Xie XY, Xie XH, Xu ZF, et al. Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis
with contrast-enhanced ultrasound. Eur Radiol 2010;20:743-53.
78. Wildner D, Pfeifer L, Goertz RS, Bernatik T, Sturm J, et al. Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of
hepatocellular carcinoma and cholangiocellular carcinoma. Ultraschall Med 2014;35:522-7.
79. Chen LD, Ruan SM, Liang JY, Yang Z, Shen SL, et al. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma
in high-risk patients: a predictive model using contrast-enhanced ultrasound. World J Gastroenterol 2018;24:3786-98.
80. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for
small hepatocellular carcinoma. Gastroenterology 2005;129:122-30.
81. Liu D, Fong DY, Chan AC, Poon RT, Khong PL. Hepatocellular carcinoma: surveillance CT schedule after hepatectomy based on risk
stratification. Radiology 2015;274:133-40.
82. Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J
Gastroenterol 2018;24:3626-36.
83. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, et al. Downstaging of hepatocellular cancer before liver transplant: long-term
outcome compared to tumors within Milan criteria. Hepatology 2015;61:1968-77.
84. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-
expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587-96.
85. Kardashian A, Florman SS, Haydel B, Ruiz RM, Klintmalm GB, et al. Liver transplantation outcomes in a U.S. multicenter cohort of 789
patients with hepatocellular carcinoma presenting beyond milan criteria. Hepatology 2020; doi: 10.1002/hep.31210.
86. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, et al. Validation of a risk estimation of tumor recurrence after transplant
(RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 2017;3:493-500.
87. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
88. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. Clinical management of hepatocellular carcinoma. conclusions of the
barcelona-2000 EASL conference. J Hepatol 2001;35:421-30.
89. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
90. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, et al. EASL and mRECIST responses are independent prognostic
factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011;55:1309-16.
91. Fournier L, Ammari S, Thiam R, Cuénod CA. Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. Diagn Interv
Imaging 2014;95:689-703.
92. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular
carcinoma. N Engl J Med 2008;359:378-90.
93. Cheng A, Kang Y, Chen Z, Tsao C, Qin S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
94. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in patients with advanced and progressing